BIONTECH SE revenue for the last year amounted to 2.75 B EUR, the most of which — 2.87 B EUR — came from its highest performing source at the moment, Immunotherapy Technologies, the year earlier bringing 3.74 B EUR. The greatest contribution to the revenue figure was made by United States — last year it brought BIONTECH SE 1.93 B EUR, and the year before that — 2.95 B EUR.